Table 1.
Patient and tumor characteristics
| Median age, years (Range) | 72 | (38–91) | |
| Thrombus level | I | 2 | (13.3%) |
| II | 5 | (33.3%) | |
| III | 4 | (26.7%) | |
| IV | 4 | (26.7%) | |
| Median thrombus diameter in cm (range) | 3 | (1–4.1) | |
| Metastatic disease | Yes | 10 | (66.7%) |
| No | 5 | (33.3%) | |
| IMDC risk group (for metastatic patients) | Good | 1 | (10.0%) |
| Intermediate | 8 | (80.0%) | |
| Poor | 1 | (10.0%) | |
| Tumor type | Clear cell | 12 | (80.0%) |
| Papillary | 1 | (6.66%) | |
| Other | 1 | (6.66%) | |
| N/A | 1 | (6.66%) | |
| Previous nephrectomy | Yes | 4 | (26.6%) |
| No | 11 | (73.3%) | |
| Systemic treatment before SAbR | Yes | 11 | (73.3%) |
| No | 4 | (26.6%) | |
| Reason for SAbR* | Progressive disease | 8 | (53.3%) |
| Palliation of symptoms | 5 | (33.3%) | |
| Other | 3 | (20.0%) | |
| Median SAbR dose in Gy (range) / No. of Fractions (range) | 40 (25–50) / 5 (1–5) | ||
| Median radio-biological equivalent dose (BED10) in Gy (range) | 72 (37.5 – 100.8) | ||
| Number of systemic treatments after SAbR | 0 | 7 | (46.6%) |
| 1 | 4 | (26.6%) | |
| 2+ | 4 | (26.6%) | |
IMDC - International Metastatic RCC Database Consortium, SAbR – Stereotactic Ablative Radiation, Gy - Gray
*
Patients may have had more than one indication